Data Program Title
Sep 2021 Neuropsychiatry / Esketamine

Safety assessment of esketamine administration via dry powder inhaler in patients with treatment-resistant bipolar depression - Posters

M. Wieczorek, S. Janowska, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

Sep 2021 Neuropsychiatry / Esketamine

Safety assessment of esketamine administered via dry powder inhaler in patients with treatment-resistant major depression - Posters

S. Janowska, M. Wieczorek, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

Sep 2021 Neuropsychiatry / Esketamine

Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration - Posters

M. Matłoka, A. Gajos-Draus, I. Majkowska, S. Kokhanovska, P. Pankiewicz, S. Janowska, K. Wójcik, M. Wieczorek, J. Pieczykolan, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

Sep 2021 Inflammatory diseases / PI3K

Potent and selective indol-4-YL pyrazolo[1,5-a]pyrimidine-derived PI3Kδ inhibitors as potential candidates for treatment of copd and asthma - Posters

Stanisław Michałek, Mariola Stypik, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Maria Bretner, Zbigniew Ochal, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster_2021

Sep 2021 Inflammatory diseases / JAK/ROCK

Novel benzimidazole-derived PI3Kδ inhibitors as highly potent drugs candidates for SLE and other inflammatory and autoimmune diseases - Posters

Mariola Stypik, Stanisław Michałek, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Zbigniew Ochal, Maria Bretner, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster 2021

 

Aug 2021 Neuropsychiatry

Antiparkinsonian - like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease - Publications

Tomasz Lenda, Krystyna Ossowska, Klemencja Berghauzen-Maciejewska, Mikołaj Matłoka, Jerzy Pieczykolan, Maciej Wieczorek, Jolanta Konieczny

publication

Aug 2021 Diabetes / GPR40

CPL207280 - a novel GPR40/FFA1 - specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals - Publications

Katarzyna Bazydlo-GuzendaPawel BudaMikolaj MatlokaMateusz MachFilip StelmachRadoslaw DzidaDamian SmugaJoanna Hucz-KalitowskaMalgorzata Teska-KaminskaVarvara VialichkaKrzysztof DubielBozena KaminskaMaciej Wieczorek and Jerzy Pieczykolan.

Jul 2021 Neuropsychiatry

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and screening for Novel TrkB Od Srthosteric Agonists - Publications

Piotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, Filip Gołębiowski, Patryk Krzemiński, Izabela Rutkowska Włodarczyk, Rafał Moszczyński Pętkowski, Lidia Gurba Bryśkiewicz, Monika Delis, Krzysztof Mulewski, Damian Smuga, Jakub Dominowski, Artur Janusz, Michał Górka, Krzysztof Abramski, Agnieszka Napiórkowska, Marcin Nowotny, Krzysztof Dubiel, Katarzyna Kalita, Maciej Wieczorek, Jerzy Pieczykolan, Mikołaj Matłoka

publication

Jun 2021 Diabetes / GPR40

Discovery and Development of CPL207280 as new GPR40/FFA1 agonist-in preparation - Publications

Jun 2021 Diabetes / GPR40

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 agonist for First-in-Human Clinical Trial - Publications

Ewelina Juszczyk, Kamil Kisło, Paweł ̇Zero, Ewa Tratkiewicz, Maciej Wieczorek, Jadwiga Paszkowska, Grzegorz Banach, Marcela Wiater, Dagmara Hoc, Grzegorz Garbacz, Jaroslaw Sczodrok, Dorota Danielak

publication

Apr 2021 Inflammatory diseases / JAK/ROCK

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus - Publications

Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan

publication

Apr 2021 Oncology / FGFR

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells - Publications

Kitowska K., Gorska-Arcisz M., Antoun D., Zarczynska I., Czaplinska D., Szczepaniak A., Skladanowski C.A., Wieczorek M., Stanczak A., Skupinska M., Sadej R.

publication

Jun 2020 Oncology / FGFR

Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) - Publications

Yamani A., Zdżalik-Bielecka D., Lipner j., Stańczak A., Piórkowska N., Stańczak P., Olejkowska P., Hucz-Kalitowska J., Magdycz M., Dzwonek K., Dubiel K., Lamparska-Przybysz M., Popiel D., Pieczykolan J., Wieczorek M.

publication

Jun 2020 Oncology / FGFR

Preclinical characterization of CPL304110 as a potential selective inhibitor of Fibroblast Growth Factors 1/2/3 in solid cancers - Posters

Popiel D., Mikołajczyk A., Skupińska M., Hucz-Kalitowska J., Stańczak P., Piorkowska N., Yamani A., Dubiel K., Stańczak A., Pieczykolan J., Wieczorek M.

poster 2020

 

Jun 2020 Oncology / FGFR

Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SQCLC) potential targeted therapy - Posters

Skupińska M., Obtułowicz T., Moes-Sosnowska J., Rozy A., Szczepulska- Wójcik E., Langfort R., Chorostowska-Wynimko J., Stańczak A., Pieczykolan J., Wieczorek M., Popiel D.

poster 2020

 

Jun 2020 Oncology / FGFR

Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression - NGS pilot study - Posters

Moes-Sosnowska J., Szczepulska-Wojcik E., Rozy A., Langfort R., Rudzinski P., Orlowski T., Skupinska M., Popiel D., Wieczorek M., Stanczak A., Chorostowska-Wynimko J.

poster 2020

Jun 2020 Diabetes / GPR40

Development of SR matrix tablet containing a new GPR40 agonist for first-in human clinical trial - Posters

Ewelina Juszczyk, Kamil Kisło, Paweł Żero, Ewa Tratkiewicz, Jadwiga Paszkowska, Dorota Danielak, Jarosław Szczodrok, Grzegorz Garbacz

poster 2020

Jun 2020 Inflammatory diseases / PI3K

Preclinical characterization of CPL302-253, a selective inhibitor of P13K, as the candidate for the inhalatory treatment and prevention of asthma - Publications

Mar 2020 Neuropsychiatry / PDE10A

The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of PD - Posters

Gajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M, Matłoka M.
Poster at the 2020 ECNP Workshop on Junior Scientists in Europe, 5-8 March 2020, Nice, France
10.1016/j.euroneuro.2019.12.006

Feb 2020 Neuropsychiatry

The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHD rat model of PD - Posters

Gajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M., Matłoka M.

poster 2020

Jun 2019 Oncology / FGFR

Efficacy study of Celon Pharma FGFR kinase inhibitor in two patient-derived tumour xenograft (PDTX) models - Posters

Hucz-Kalitowska J., Teska-Kamińska M., Stańczak A., Skupińska M., Mikołajczyk A., Pieczykolan J., Wieczorek M.,

poster 2019

Jun 2019 Neuropsychiatry / Esketamine

Safety assessment of esketamine administered via dry powder inhalation in animals and humans during preclinical toxicology and phase I clinical study - Posters

Matłoka M., Janowska J., Sierzputowska J., Jarus-Dziedzic K., Pieczykolan J., Wieczorek M.

poster 2019

Jun 2019 Neuropsychiatry / Esketamine

Safety and pharmacokinetic study of inhaled esketamine after a multiple dose in healthy volunteers - Posters

Janowska S., Tratkiewicz E., Matłoka M., Perko P., Gaciarz  M., Wieczorek M.

poster 2019

 

Jun 2019 Neuropsychiatry / PDE10A

Safety and pharmacokinetic study of phosphodiesterase 10A inhibitor ( CPPL500036 ) after a single dose in healthy volunteers - Posters

Janowska S., Jarus-Dziedzic K., Sierzputowska J., Matłoka M., Wieczorek M.

poster 2019

Oct 2018 Neuropsychiatry / Esketamine

Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers - Posters

Janowska S., Tratkiewicz E., Matłoka M., Perko P., Gaciarz M., Wieczorek M.

poster 2018

Oct 2018 Diabetes / GPR40

Novel GPR40 agonist CPL-207-280 independently improves glycaemia and mitigates neuropathic pain in diabetic rodents - Posters

Paweł Buda, Katarzyna Bazydło-Guzenda, Mateusz Mach, Filip Stelmach, Radosław Dzida, Joanna Hucz-Kalitowska, Małgorzata Teska-Kaminska, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster 2018

Oct 2018 Neuropsychiatry / PDE10A

Novel and highly bioavailable PDE10A inhibitor activates cyclic nucleotides depending signaling in rat striatum - Posters

Pankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Kokhanovska S., Janicka M., Hucz-Kalitowska J., Świątkieicz M., Wełniak-Kamińska M., Fiedorowicz M., Grieb P., Pieczykolan J., Wieczorek M., Matłoka M.

poster 2018

 

Sep 2018 Neuropsychiatry / Esketamine

pharmacodynamics-of-s-ketamine-and-ketamine-racemate-in-rat-pfc-and-hp-after-dry-powder-inhalation-intratracheal-and-intravenous-administration - Posters

Ketamine High Dose Dry Powder Composition for Pulmonary Administration, Gajos-Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matloka M.
Poster at 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.

Sep 2018 Neuropsychiatry / PDE10A

cpl-500-036-02-novel-and-highly-bioavailable-pde10a-inhibitor-activates-cyclic-nucleotides-depending-signaling-in-rat-striatum - Posters

Pankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Janicka M., Hucz-Kalitowska J., Świątkiewicz M., Wełniak-Kamińska M., Fiedorowicz M. Grieb P., Pieczykolan J., Wieczorek M., Matłoka M.
Poster at the 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.
https://doi.org/10.1016/j.euroneuro.2018.11.798

Sep 2018 Neuropsychiatry / Esketamine

safety-and-pharmacokinetics-study-of-inhaled-esketamine-after-a-single-dose-in-healthy-volunteers - Posters

Janowska, S., Tratkiewicz, E., Matloka, M., Perko, P., Gaciarz, M., Urban, A., Wieczorek, M.
Poster at 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.

Jul 2018 Neuropsychiatry / 5-HT6R

Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in thescaffold on affinity - Publications

Grychowska, Rafał Kurczab, Paweł Śliwa, Grzegorz Satała, Krzysztof Dubiel, Mikołaj Matłoka, Rafał Moszczyński-Pętkowski, Jerzy Pieczykolan, Andrzej J. Bojarski, Paweł Zajdel Bioorganic & Medicinal Chemistry Volume 26, Issue 12, 23 July 2018, Pages 3588-3595 doi: 10.1016/j.bmc.2018.05.033

Jul 2018 Oncology / FGFR

The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine - based chemotherapy - Posters

Skupińska M., Jesiotr M., Chrom P., Mróz A., Cierniak S., Winiarek M., Wyrwicz L., Pieczykolan J., Wieczorek M., Stańczak A., Bodnar L.

poster 2018

Jun 2018 Oncology

Rational-based drug design of novel, highly potent MER inhibitors as potential treatment of cancers - Posters

Mikolajczyk A., Yamani A., Olejkowska P., Piorkowska N., Naitana M., Maliszewski P., Dubiel K., Pieczykolan J., wieczorek M., Stanczak A.

poster 2018

Jun 2018 Oncology

CPL-410-005, a novel ubiquitin-activating enzyme (UAE) inhibitor in preclinical evaluation as ananticancer treatment for solid tumours - Posters

Kozłowska D., Górnicka A., Stypik B., Mroczkiewicz M., Mikolajczyk A., Hucz-Kalitowska J.,Szwalbe A., Mulewski K., Smuga D., Dubiel K., Pieczykolan J., Wieczorek M., Stańczak A.

poster 2018

 

Jun 2018 Oncology / FGFR

Analiza mutacji FGFR3 w grupie 116 pacjentów z niezaawansowaną postacią raka pęcherza moczowego - Posters

Gapska P., Sosnowski R., Stajno P., Ligaj M., Prochorec-Sobieszek M., Pieczykolan J., Wieczorek M., Demkow T., Stańczak A.

poster 2018

 

Jun 2018 Oncology / FGFR

Search for predictive biomarkers of sensitivity/resistance against novel FGFR inhibitor using array-based comparative genomic hybridization(aCGH) and RNA sequencing (RNAseq)-preliminary results - Posters

Cortez A.J., Kujawa K.A., Tudrej P.A., Kitowska K., Sądej R., Student S., Klyszcz K., Lisowska K.M.

poster 2018

Jun 2018 Neuropsychiatry / Esketamine

Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies and influence of nitrogen atom position in thescaffold on affinity - Publications

Bioorganic & Medicinal Chemistry doi: 10.1016/j.bmc.2018.05.033,

Jun 2018 Neuropsychiatry / Esketamine

LC-MS/MS chiral method for simultaneous determination of RS-ketamine and its metabolites in rat plasma and brain samples frpm pharmacokinetic studies - Posters

Janicka M., Matłoka M., Mach M., Moszczyński-Pętkowski R., Pieczykolan J., Tratkiewicz E., Wieczorek M.

poster 2018

Jun 2018 Neuropsychiatry / Esketamine

Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - Posters

Matłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M.

poster 2018

Jun 2018 Neuropsychiatry / Esketamine

Pharmacodynamics of S-ketamine and ketamine racemate in rat PFC and HP after dry powder inhalation, intratracheal nd intravenous administration - Posters

Gajos- Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matłoka M.

poster 2018

Jun 2018 Diabetes / GPR40

Discovery of CPL 207-280CA, an effective and safe GPR40 agonist for the treatment of type 2 diabetes - Posters

Katarzyna Bazydło, Paweł Buda, Mateusz Mach, Radosław Dzida, Filip Stelmach, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

 poster 2018

May 2018 Neuropsychiatry / PDE10A

Synthesis and characterization of novel classes of PDE10A inhibitors - 1H - 1,3-benzodiazoles and imidazo [1,2-a] pyrimidines - Publications

Rafał Moszczyński-Pętkowski, Jakub Majer, Małgorzata Borkowska, Łukasz Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel, Maciej Wieczorek, European Journal of Medicinal Chemistry

publication

May 2018 Neuropsychiatry / Esketamine

Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - Posters

Matłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M.
Poster at the 2018 APA Annual Meeting, 5-9 May 2018, New York City, USA.

Jun 2017 Oncology

Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy - Posters

Stańczak A., Górnicka A., Stypik B., Mroczkiewicz M., Pieczykolan J., Dubiel K., Wieczorek M.

poster 2017

Jun 2017 Oncology / FGFR

Low consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer (SQCLC) - Posters

Chorostowska-Wynimko J., Skupinska M.M., Rozy A., Siewiera K., Szczepulska E., Langfort R., Rudzinski P., Orlowski T., Wieczorek M., Stanczak A.

poster 2017

Jun 2017 Oncology / FGFR

Ovarian cancer cells show enhanced response to the novel FGFR inhibitor CPL-304-110 - Posters

Kujawa K.A., Rusin A. Olbryt M., Tudrej P., Cortez A.J., Stanczak A., Wieczorek M., Lisowska K.M.

poster 2017

Jun 2016 Neuropsychiatry

The modulation of cyclic nucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10A inhibitor - Posters

Sylwia Janowska, Piotr Pankiewicz, Maciej Świątkiewicz, Marlena Wełniak-Kamińska, Małgorzata Borkowska, Jakub Majer, Rafał Moszczyński-Pętkowki, Krzysztof Dubiel, Maciej Wieczorek, Mikołaj Matłoka

poster 2016

May 2016 Neuropsychiatry / PDE10A

Development of the novel and selective inhibitor of phosphodiesterase 10A-CPL-500-036-02 and exploring its mode of action - Posters

Mikołaj Matłoka, Katarzyna Bieganska, Sylwia Janowska, Piotr Pankiewicz, Katarzyna Kalita, Jerzy Pieczykolan, Leszek Kaczmarek, Maciej Wieczorek

poster 2016

Apr 2016 Neuropsychiatry / PDE10A

The modulation of cyclicnucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10a inhibitor. - Publications

Janowska S, Pankiewicz P, Swiatkiewicz M, Welniak-Kaminska M, Borkowska M, Majer J, Moszczynski-Petkowski R, Dubiel K, Wieczorek M, Matloka M.
Poster at the 5th Schizophrenia International Research Society Conference, 2 – 6 April 2016, Florence, Italy

Oct 2015 Inflammatory diseases / JAK/ROCK

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - Publications

Pawel Gunerka;  Barbara Dymek; Aleksandra Stanczak; Anna Bujak; Paulina Grygielewicz; Pawel Turowski; Karolina Dzwonek; Monika Lamparska-Przybysz; Tadeusz Pietrucha; Maciej Wieczorek, European Journal of Pharmacology Volume 765, 15 October 2015, Pages 188–197 doi:10.1016/j.ejphar.2015.08.037

Aug 2015 Inflammatory diseases / JAK/ROCK

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - Publications

Paweł  Gunerka, Barbara Dymek, Aleksandra Stanczak, Anna Bujak, Paulina Grygielewicz, Paweł Turowski, Karolina Dzwonek, Monika Lamparska-Przybysz, Tadeusz Pietrucha, Maciej Wieczorek, European Journal of Pharmacology 2015, doi:10.1016/j.ejphar.2015.08.037

publication

Jun 2015 Oncology / FGFR

Analysis of the intra-tumor heterogeneity and consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer - Posters

Skupinska M., Jagus P., Grygielewicz P., Mikolajczyk A., Szczepulska E., Rozy A., Langfort R., Chorostowska-Wynimko J., Wieczorek M., Stanczak A.

poster 2015

 

Jun 2015 Oncology / FGFR

Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy - Posters

Grygielewicz P., PiorkowskaN., Mikołajczyk A., Hucz-Kalitowska J.,Yamani A., Dubiel K., Wiecorek M., stanczak A.

poster 2015

May 2015 Inflammatory diseases / JAK/ROCK

Highly active and selective JAK2 inhibitor CPL-407-220 as a new drug candidate for myeloproliferative disorders - Posters

Anna Bujak, Paweł Gunerka1, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek

Posters 1.InnovativeDrugsR&DDepartment, Celon Pharma S.A., Lomianki, Poland; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University,Poland; 3.Department of Medical Biotechnology, Medical University of Lodz, Poland

poster 2015

Apr 2015 Inflammatory diseases / JAK/ROCK

Novel, highly potent and selective JAK3 inhibitor CPL-409-057 disrupting IL-4/IL-13 signaling in asthma therapy - Posters

Anna Bujak, Paweł Gunerka, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek

Poster 1.Celon Pharma S.A., Lomianki; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University; 3. Department of Medical Biotechnology, Medical University of Lodz, Poland

poster 2015

 

Mar 2015 Inflammatory diseases / PI3K

Pharmacokinetics of selective P13K inhibitors after intratracheal instillation in mice - Posters

Pawel Turowski, Paweł Gunerka, , Joanna Hucz-Kalitowska, Marcin Zagozda, Maciej Dziachan, Mariola Sekular, Anna Bujak,Maciej Wieczorek

Poster 11Innovative DrugsR&DDepartment, Celon Pharma S.A., Kielpin, Lomianki, Poland 2Postgraduate Schoolof MolecularMedicine, Warsaw Medical University, Warsaw,Poland 3Department of Medical Biotechnology, Medical University of Lodz, Lodz, Poland

poster 2015

Nov 2014 Oncology / FGFR

Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells, - Publications

Grygielewicz P1, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, Zdzalik D, Gastric Cancer 2014 Nov 19

Apr 2014 Oncology

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. - Publications

Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K., J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98

Feb 2014 Oncology

Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer - Publications

Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, Szczylik C, Wieczorek M, Lamparska-Przybysz M. J, Ovarian Res. 2014 Feb 6;7:16.

Dec 2011 Oncology

Prognostic significance of Wnt-1, ß-catenin and E-cadherin expression in advanced colorectal carcinoma - Publications

Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M, Lamparska-Przybysz M, Pathol Oncol Res. 2011 Dec;17(4):955-63.

Dec 2010 Neuropsychiatry / PDE10A

In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia - Publications

Bojarski L, Debowska K, Wojda U., Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1367-74.

Jul 2008 Oncology

Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells - Publications

Wieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK, Lamparska-Przybysz M. . Cancer Biol Ther. 2008 Feb;7(2):268-74.